Table 4 Patients’ response to treatment
From: The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt
Response | P value* | ||
|---|---|---|---|
Non-Responding (20) (SD,PD) | Responding (61) (CR,PR) | ||
Age | |||
< 40 (39) | 5(25.0%) | 34(55.7%) | 0.017a |
≥ 40 (42) | 15(75.0%) | 27(44.3%) | |
Gender | |||
Male (51) | 11(55.0%) | 40(65.6%) | 0.40 a |
Female (30) | 9(45.0%) | 21(34.4%) | |
B-symptoms | |||
Negative (59) | 15(75.0%) | 44(72.1%) | 0.80 a |
Positive (22) | 5(25.0%) | 17(27.9%) | |
Bulky disease | |||
Negative (66) | 16(80.0%) | 50(82.0%) | 0.84 a |
Positive (15) | 4(20.0%) | 11(18.0%) | |
IPS | |||
Low risk (62) | 15(75.0%) | 47(77.0%) | 0.85 a |
High risk (19) | 5(25.0%) | 14(23.0%) | |
Stage | |||
Early (33) | 4(20.0%) | 29(47.5%) | 0.03a |
Advanced (48) | 16(80.0%) | 32(52.5%) | |
CD20-IHC | |||
Negative (13) | 7(35.0%) | 6(9.8%) | |
Low-expression (30) | 12(60.0) | 18(29.5%) | < 0.001b |
Moderate-expression (17) | 1(5.0%) | 16(26.2%) | |
High-expression (21) | 0(0.0%) | 21(34.4%) | |
CD68-mRNA | |||
Negative (38) | 2(10.0%) | 36(59.0) | < 0.001a |
Positive (43) | 18(90.0%) | 25(41.0) | |
CD68-IHC | |||
Negative (24) | 1(5.0%) | 23(37.7%) | < 0.001b |
Low-expression (15) | 0(0.0%) | 15(24.6%) | |
Moderate-expression (15) | 3(15.0%) | 12(19.7%) | |
High-expression (27) | 16(80.0%) | 11(18.0%) | |
CD68 cell count | |||
< 20 cells | 3(15.0%) | 39(63.9%) | < 0.001a |
≥ 20 cells | 17(85.0%) | 22(36.1%) | |